Industry eyes on a model that could plug the pharma gap

25 September 2017

There has been plenty of reaction on Monday to the news that the world’s biggest pharma company is effectively launching a start-up that it believes has a better chance of developing some of its drugs successfully.

SpringWorks Therapeutics was conceived by the US pharma giant Pfizer (NYSE: PFE). It has launched with a completed $103 million Series A financing that was also funded by US firms Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed and UK-government-backed research charity LifeArc.

"SpringWorks started as an idea about a new way to get things done"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK